SET-mediated PP2A inactivation is essential for survival/self-renewal of quiescent CML HSCs and maintenance of an active Jak2-β-catenin pathway and that PP2A is suppressed in CML HSCs in a BCR/ABL kinase-independent, Jak2-dependent manner (27). The gene discussed is PTPA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.